Pneumovax 23

also known as 23-valent pneumococcal polysaccharide vaccine · PPV23 · Pneumovax · PPSV23 · Pneumo23 · Pneumococcal polysaccharide vaccine · pneumococcal polyvalent vaccine · 23-valent polysaccharide pneumococcal vaccine · +26 more

Vaccine

Developed for: pneumococcal infection · chronic lymphocytic leukemia/small lymphocytic lymphoma · streptococcal pneumonia · asthma · chronic obstructive pulmonary disease · plasma cell myeloma · pneumonia · disease related to solid organ transplantation
+7 more
· idiopathic severe pneumococcemia · infectious disease · pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma · streptococcal infection · acute lymphoblastic leukemia · bacterial pneumonia · meningitis
Investigated by: Merck Sharp & Dohme LLC · GlaxoSmithKline · National Institute of Allergy and Infectious Diseases (NIAID) · China National Biotec Group Company Limited · Mayo Clinic · National Cancer Institute (NCI)
+102 more
· Wyeth is now a wholly owned subsidiary of Pfizer · Assistance Publique - Hôpitaux de Paris · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Changchun Institute of Biological Products Co., Ltd. · Chengdu Institute of Biological Products Co.,Ltd. · Sinovac Biotech Co., Ltd · Centers for Disease Control and Prevention · Centers for Disease Control and Prevention, China · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Ewha Womans University · Genentech, Inc. · Pfizer · Shanghai Municipal Center for Disease Control and Prevention · Sichuan Center for Disease Control and Prevention · URC-CIC Paris Descartes Necker Cochin · University Health Network, Toronto · University of Maryland Greenebaum Cancer Center · VA Office of Research and Development · AZ Sint-Jan AV · Aghia Sophia Children's Hospital of Athens · Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · Alaska Native Tribal Health Consortium · Albert Einstein College of Medicine · Asan Medical Center · Astellas Pharma Inc · Beijing Institute of Biological Products Co Ltd. · Bill and Melinda Gates Foundation · Biogen · CIC 1417 Cochin-Pasteur · CIHR Canadian HIV Trials Network · Cedars-Sinai Medical Center · Celgene Corporation · Center for Disease Control and Prevention, Fujian · Chung-Ang University Hospital · EUCLID Clinical Trial Platform · Eli Lilly and Company · Emory University · Far Eastern Memorial Hospital · Finnish Institute for Health and Welfare · Fondo de Investigacion Sanitaria · French National Institute of Health and Medical Research · Groupe Français d'Etude des Vascularites (GFEV) · Guangdong Center for Disease Prevention and Control · Guizhou Center for Disease Control and Prevention · Henan Center for Disease Control and Prevention · Hospital Son Llatzer · Hospital Universitari Son Dureta · Hubei Provincial Center for Disease Control and Prevention · Hunan Provincial Center for Disease Control and Prevention · Inje University · International Centre for Diarrhoeal Disease Research, Bangladesh · Jena University Hospital · Jiangsu Province Centers for Disease Control and Prevention · Johns Hopkins Bloomberg School of Public Health · KEMRI-Wellcome Trust Collaborative Research Program · KU Leuven · Kaiser Permanente · Keimyung University Dongsan Medical Center · Konkuk University Hospital · Korea University · Kosin University Gospel Hospital · Kyunghee University Medical Center · Medical University of South Carolina · Michael E. DeBakey VA Medical Center · Mikhael Petrovich Kostinov · Montefiore Medical Center · National Heart, Lung, and Blood Institute (NHLBI) · National Institutes for Food and Drug Control, China · Peking University · Poitiers University Hospital · Recherche Clinique Paris Descartes Necker Cochin Sainte Anne · Region Örebro County · Rohit Divekar · Ruijin Hospital · all 108 on the full record

Trials 92 · started per year

today

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT03449459	Dec 2018 → Dec 2020	chronic obstructive pulmonary disease	Shanghai Zhongshan Hospital	Completed	No outcome recorded
Phase 0	NCT03802994	Nov 2018 → Feb 2020	—	VA Office of Research and Development	Terminated	No outcome recorded
Phase 0	NCT03039491	Sep 2015 → Mar 2020	lipodystrophy	Medical University of South Carolina	Completed	No outcome recorded
Phase 0	NCT01239875	Nov 2010 → Nov 2015	MALT lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, grade III lymphomatoid granulomatosis +6	Mayo Clinic	Completed	No outcome recorded
Phase 17 trials
Phase 1	NCT05163834	Nov 2021 → Mar 2022	—	argenx	Completed	No outcome recorded
Phase 1	NCT02719379	Apr 2016 → Jun 2017	asthma	Rohit Divekar	Completed	No outcome recorded
Phase 1	NCT02543918	Sep → Nov 2015	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT00589394	Jul 2007 → Dec 2008	—	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT00479323	Jun 2007 → Aug 2008	pneumococcal infection	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT03460730	Nov 2004 → Jul 2006	streptococcal pneumonia	KEMRI-Wellcome Trust Collaborative Research Program	Completed	No outcome recorded
Phase 1	NCT00153543	May 2002 → Jun 2003	pneumococcal infection	Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 1/26 trials
Phase 1/2	NCT06703203	Jul → Aug 2025	—	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 1/2	NCT00499577	Dec 2006 → Feb 2009	plasma cell myeloma	University of Maryland Greenebaum Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00137605	Sep 2004 → Oct 2007	pneumococcal infection	CIHR Canadian HIV Trials Network	Completed	No outcome recorded
Phase 1/2	NCT00142389	Aug 2004 → Dec 2006	pneumococcal infection	Johns Hopkins Bloomberg School of Public Health	Completed	No outcome recorded
Phase 1/2	NCT00169234	May 2003 → Feb 2005	pneumonia	Kaiser Permanente	Completed	No outcome recorded
Phase 1/2	NCT00046852	Dec 2001 → Nov 2004	infectious disease, plasma cell myeloma	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 214 trials
Phase 2	NCT05417165	Sep 2023 → Oct 2026 expected	chronic lymphocytic leukemia/small lymphocytic lymphoma	Seema Bhat	Recruiting	No outcome recorded
Phase 2	NCT05183854	Jan 2022 → Mar 2027 expected	chronic lymphocytic leukemia/small lymphocytic lymphoma	University of Utah	Recruiting	No outcome recorded
Phase 2	NCT03069703	Feb 2018 → Nov 2020	pneumococcal infection	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT02717494	Mar 2016 → Nov 2018	congenital human immunodeficiency virus	Westat	Completed	No outcome recorded
Phase 2	NCT02097849	Feb 2015 → May 2016	relapsing-remitting multiple sclerosis	Biogen	Completed	No outcome recorded
Phase 2	NCT02052154	Mar 2014 → Jul 2016	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT02274415	Sep 2013 → Sep 2017	pneumococcal infection, sickle cell disease	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT01351896	Nov 2011 → Jul 2024 overdue	pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2	NCT00445484	Jan 2007 → Apr 2009	plasma cell myeloma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 2	NCT00282308	Jan 2006 → Jan 2008	rheumatoid arthritis	Genentech, Inc.	Completed	No outcome recorded
Phase 2	NCT00170612	Nov 2005 → Jan 2008	pneumococcal infection	University of Melbourne	Completed	No outcome recorded
Phase 2	NCT00307567	Nov 2005 → Mar 2006	diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00307008	Oct 2003 → Feb 2005	pneumococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00133549	Nov 2000 → Dec 2002	pneumococcal infection	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 321 trials
Phase 3	NCT06044077	Sep 2023 → Mar 2024 overdue	pneumococcal infection	Aimei Vacin BioPharm (Zhejiang) Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT06314867	Jan 2023 → Dec 2024 overdue	—	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Active not recruiting	No outcome recorded
Phase 3	NCT05158140	Jan 2022 → Feb 2023	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT05028634	Nov 2021 → Nov 2023	relapsing-remitting multiple sclerosis	Celgene Corporation	Completed	No outcome recorded
Phase 3	NCT03565900	Sep 2018 → Nov 2021	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03547167	Jul 2018 → Jan 2020	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03480802	Jul 2018 → Sep 2019	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03480763	Jun 2018 → Dec 2019	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT04278248	Jan → Jun 2018	streptococcal pneumonia	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 3	NCT02218697	Oct 2014 → Jan 2015	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02225587	Aug 2014 → Jul 2015	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT02045836	Mar 2014 → Jul 2015	herpes zoster	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01734239	Jun → Oct 2013	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00999739	Dec 2007 → Apr 2008	HIV infectious disease	Hospital Universitari Son Dureta	Unknown	No outcome recorded
Phase 3	NCT00574548	Nov 2007 → Feb 2010	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00594347	Nov 2007 → Mar 2008	pneumococcal infection	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00560950	Jul 2007 → May 2008	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00535730	Jun 2007 → Feb 2008	herpes zoster, pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00333450	Aug → Dec 2006	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00169507	Mar → Apr 2005	idiopathic severe pneumococcemia	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00127153	Mar → May 2005	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded

Phase 433 trials
Phase 4	NCT07640841	Jun 2026 → Jun 2027 expected	—	Jiangsu Province Centers for Disease Control and Prevention	Not yet recruiting	No outcome recorded
Phase 4	NCT05731115	Feb → May 2023	pneumococcal infection	Sinovac Biotech Co., Ltd	Completed	No outcome recorded
Phase 4	NCT05170399	Sep 2022 → Aug 2026 overdue	lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	No outcome recorded
Phase 4	NCT05471531	Nov 2021 → Mar 2022	—	Sinovac Biotech Co., Ltd	Completed	No outcome recorded
Phase 4	NCT05499351	Oct → Dec 2021	COVID-19	Sinovac Biotech Co., Ltd	Completed	No outcome recorded
Phase 4	NCT05298800	Oct 2021 → Dec 2022	—	Centers for Disease Control and Prevention, China	Unknown	No outcome recorded
Phase 4	NCT04460235	Sep 2021 → Jun 2028 expected	non-Hodgkin lymphoma, pneumococcal infection	Poitiers University Hospital	Recruiting	No outcome recorded
Phase 4	NCT05079152	May 2021	influenza, streptococcal pneumonia	China National Biotec Group Company Limited	Unknown	No outcome recorded
Phase 4	NCT04481243	Apr 2021 → Jan 2023	type 1 diabetes mellitus	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT04875819	Apr 2021 → Dec 2026 expected	HIV infectious disease, meningococcal infection, pneumococcal infection	Thomas Benfield	Recruiting	No outcome recorded
Phase 4	NCT04701788	Mar → Dec 2021	—	China National Biotec Group Company Limited	Completed	No outcome recorded
Phase 4	NCT04700618	Mar → Aug 2021	—	China National Biotec Group Company Limited	Completed	No outcome recorded
Phase 4	NCT04790851	Mar → Sep 2021	COVID-19, influenza, streptococcal pneumonia	China National Biotec Group Company Limited	Completed	No outcome recorded
Phase 4	NCT04559204	Sep → Nov 2020	influenza, streptococcal pneumonia	China National Biotec Group Company Limited	Completed	No outcome recorded
Phase 4	NCT05316831	Jan 2019 → Jun 2021	chronic lymphocytic leukemia/small lymphocytic lymphoma	Region Örebro County	Completed	No outcome recorded
Phase 4	NCT02637583	Oct 2017 → Nov 2022	pneumococcal infection	Jena University Hospital	Completed	No outcome recorded
Phase 4	NCT03260790	Oct 2017 → Dec 2020	asthma	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT03041051	Dec 2015 → Mar 2017	HIV infectious disease	Aghia Sophia Children's Hospital of Athens	Unknown	No outcome recorded
Phase 4	NCT02429531	Oct 2015 → Aug 2018	immunodeficiency due to selective anti-polysaccharide antibody deficiency	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
Phase 4	NCT02260882	Oct 2014 → Apr 2015	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT02072525	Apr 2014 → Jun 2015	meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02492438	Feb 2013 → Feb 2014	chronic renal failure syndrome	AZ Sint-Jan AV	Completed	No outcome recorded
Phase 4	NCT02787863	Sep 2012 → Dec 2016	asthma, chronic obstructive pulmonary disease, pneumococcal infection	Mikhael Petrovich Kostinov	Completed	No outcome recorded
Phase 4	NCT01505855	Dec 2011 → Jun 2013	Crohn disease	Kyunghee University Medical Center	Completed	No outcome recorded
Phase 4	NCT01163747	Sep 2010 → Dec 2011	rheumatoid arthritis	Genentech, Inc.	Completed	No outcome recorded
Phase 4	NCT00919321	Jun 2009 → Dec 2013	chronic lymphocytic leukemia/small lymphocytic lymphoma	Tampere University Hospital	Completed	No outcome recorded
Phase 4	NCT01381367	Feb 2009 → Jun 2011	chronic obstructive pulmonary disease	Far Eastern Memorial Hospital	Completed	No outcome recorded
Phase 4	NCT00493324	Jul 2007 → Jul 2008	psoriasis	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT00964769	Apr → May 2005	—	Ewha Womans University	Completed	No outcome recorded
Phase 4	NCT00152802	Jan 2005 → Jan 2009	disease related to solid organ transplantation	University Health Network, Toronto	Unknown	No outcome recorded
Phase 4	NCT00304382	Jan 2003 → Sep 2006	pneumococcal infection, pneumonia	VA Office of Research and Development	Completed	No outcome recorded
Phase 4	NCT00143780	May 2002 → Jul 2006	bone marrow disorder	University Health Network, Toronto	Completed	No outcome recorded
Phase 4	NCT00368186	May 2001 → Nov 2002	pneumococcal infection	Wyeth is now a wholly owned subsidiary of Pfizer	Terminated	No outcome recorded

Phase not applicable7 trials
—	NCT02707692	Aug 2016 → Apr 2020	AIDS	University of California, San Diego	Completed	No outcome recorded
—	NCT02126384	Nov 2014 → Apr 2016	pneumococcal infection	French National Institute of Health and Medical Research	Completed	No outcome recorded
—	NCT02012309	Aug 2014 → Jun 2021	HIV infectious disease, pneumococcal infection	University of Colorado, Denver	Unknown	No outcome recorded
—	NCT01307449	Apr 2014 → Jul 2017	pneumococcal infection	Emory University	Completed	No outcome recorded
—	NCT00706550	Oct 2008 → Sep 2011	HIV infectious disease	US Department of Veterans Affairs	Completed	No outcome recorded
—	NCT00257127	Feb → Aug 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00829595	May 2005 → Dec 2007	Crohn disease, ulcerative colitis	Cedars-Sinai Medical Center	Completed	No outcome recorded

Also used as a comparator or background therapy in 82 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT07025876 Comparator	Nov 2023 → Jun 2024	streptococcal pneumonia	Jiangsu Province Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 0	NCT05346302 Comparator	Feb → Dec 2022	inflammatory disease	Texas A&M University	Completed	No outcome recorded
Phase 0	NCT02558751 Comparator	Jul 2013 → Jun 2015	pneumococcal infection	University of Toledo Health Science Campus	Completed	No outcome recorded
Phase 0	NCT02515240 Comparator	Jul 2010 → Jun 2014	pneumococcal infection	University of Toledo Health Science Campus	Completed	No outcome recorded
Phase 114 trials
Phase 1	NCT06474377 Comparator	Jun → Aug 2024	pneumococcal infection	Sinovac Life Sciences Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT06056050 Comparator	Dec 2023 → Apr 2024 overdue	diphtheria, pertussis, tetanus	CanSino Biologics Inc.	Active not recruiting	No outcome recorded
Phase 1	NCT06678607 Comparator	Nov 2023 → Jul 2024	pneumococcal infection	Shanghai Reinovax Biologics Co.,LTD	Completed	No outcome recorded
Phase 1	NCT04054752 Comparator	May → Nov 2023	breast carcinoma, colorectal adenocarcinoma, urinary bladder carcinoma	National Cancer Institute (NCI)	Withdrawn	No outcome recorded
Phase 1	NCT05827874 Background	Apr → Oct 2023	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT05622942 Comparator	Mar → Sep 2023	pneumonia	CanSino Biologics Inc.	Completed	No outcome recorded
Phase 1	NCT05667740 Comparator	Jan → Oct 2023	pneumococcal infection	GPN Vaccines	Completed	No outcome recorded
Phase 1	NCT04665050 Comparator	Feb → Apr 2021	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT05815264 Comparator	Sep 2020 → Apr 2021	pneumonia	Ab&B Bio-tech Co., Ltd.JS	Completed	No outcome recorded
Phase 1	NCT04265911 Comparator	Feb → Nov 2020	—	Affinivax, Inc.	Completed	No outcome recorded
Phase 1	NCT02097589 Background	Jun → Sep 2014	—	University of Florida	Completed	No outcome recorded
Phase 1	NCT00756067 Comparator	Sep 2008 → May 2009	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00707798 Comparator	Jun 2008 → Jan 2009	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00327665 Comparator	May 2006 → Jan 2007	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded

Phase 1/27 trials
Phase 1/2	NCT07600983 Comparator	May → Nov 2026 expected	pneumococcal infection	CanSino Biologics Inc.	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07418372 Comparator	Mar → Aug 2026 overdue	diphtheria, pertussis, tetanus	Institute of Medical Biology, Chinese Academy of Medical Sciences	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07543198 Comparator	Jun 2025 → Feb 2026	pneumococcal infection	Sinovac Life Sciences Co., Ltd.	Completed	No outcome recorded
Phase 1/2	NCT05982314 Comparator	Jul 2023 → Aug 2024	pneumococcal infection	GPN Vaccines	Completed	No outcome recorded
Phase 1/2	NCT04168190 Comparator	Dec 2019 → Jul 2021	streptococcal pneumonia	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1/2	NCT03803202 Comparator	Jan 2019 → Sep 2020	bacterial pneumonia, pneumococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 1/2	NCT02308540 Comparator	Jan 2015 → Apr 2016	pneumococcal infection	PATH	Completed	No outcome recorded

Phase 214 trials
Phase 2	NCT06678620 Comparator	Apr 2024 → Apr 2025 overdue	pneumococcal infection	Shanghai Reinovax Biologics Co.,LTD	Active not recruiting	No outcome recorded
Phase 2	NCT07035054 Comparator	Apr → Nov 2024	streptococcal pneumonia	Jiangsu Province Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 2	NCT04583618 Comparator	Oct 2020 → Aug 2021	—	Sanofi	Completed	No outcome recorded
Phase 2	NCT03873727 Background	Aug 2019 → May 2022	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT03313050 Comparator	Oct 2017 → May 2019	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 2	NCT03313037 Comparator	Oct 2017 → Dec 2018	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 2	NCT02255227 Background	Apr 2015 → Aug 2019	inflammatory bowel disease, pneumococcal infection	University Hospital of Saint-Etienne	Terminated	No outcome recorded
Phase 2	NCT02279589 Comparator	Dec 2014 → Jun 2016	pneumococcal infection	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT02232191 Comparator	Dec 2014 → Jul 2026 overdue	—	University of California, Davis	Recruiting	No outcome recorded
Phase 2	NCT01513551 Comparator	Mar 2012 → Feb 2013	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT01414504 Comparator	Dec 2009 → Sep 2011	—	William Pomat	Completed	No outcome recorded
Phase 2	NCT00788151 Comparator	Sep 2008 → Feb 2010	Dengue hemorrhagic fever	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00307528 Comparator	Jan 2004 → Mar 2005	—	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT02806284 Comparator	Jan 2001 → Jan 2008	meningitis	Uppsala University	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT06708286 Comparator	Dec 2024 → May 2025 overdue	diphtheria, pertussis, tetanus	CanSino Biologics Inc.	Active not recruiting	No outcome recorded
Phase 2/3	NCT00611663 Background	May 2008 → Dec 2014	systemic lupus erythematosus	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2/3	NCT00339157 Comparator	May 2006 → Jun 2008	systemic-onset juvenile idiopathic arthritis	French National Institute of Health and Medical Research	Completed	No outcome recorded
Phase 322 trials
Phase 3	NCT06177912 Comparator	Jan 2024 → Feb 2025	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT05696080 Comparator	Feb 2023 → Feb 2024	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT05633992 Comparator	Jan → May 2023	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT05569954 Comparator	Nov 2022 → Oct 2023	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT05464420 Comparator	Aug 2022 → May 2023	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT05393037 Comparator	Jul 2022 → Jul 2023	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT05420961 Comparator	Jul 2022 → May 2023	streptococcal pneumonia	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT04875533 Comparator	Jun 2021 → May 2022	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT04214444 Background	Jul 2020 → May 2024	diffuse large B-cell lymphoma, pneumococcal infection	University Hospital, Tours	Completed	No outcome recorded
Phase 3	NCT03921424 Background	Nov 2019 → May 2021	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03835975 Comparator	Feb 2019 → Feb 2020	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT03760146 Comparator	Dec 2018 → Dec 2019	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT02451969 Comparator	Apr → Jun 2015	pneumococcal infection	Sinovac Biotech Co., Ltd	Completed	No outcome recorded
Phase 3	NCT01942174 Background	Sep 2013 → Aug 2018	rheumatoid arthritis	University Hospital, Montpellier	Completed	No outcome recorded
Phase 3	NCT01892618 Comparator	Aug 2013 → Dec 2015	chronic lymphocytic leukemia/small lymphocytic lymphoma	Karolinska University Hospital	Completed	No outcome recorded
Phase 3	NCT02285036 Comparator	Sep → Dec 2012	pneumococcal infection	Walvax Biotechnology Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01646398 Comparator	Jun → Oct 2012	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT01451086 Comparator	Oct 2011 → Jul 2012	—	Jiangsu Province Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 3	NCT00785967 Background	Jan 2009 → Aug 2011	HIV infectious disease	McGill University Health Centre/Research Institute of the McGill University Health Centre	Withdrawn	No outcome recorded
Phase 3	NCT00457977 Comparator	Mar 2007 → May 2011	chronic obstructive pulmonary disease	University of Minnesota	Completed	No outcome recorded
Phase 3	NCT00427895 Comparator	Feb 2007 → Aug 2011	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT00622843 Comparator	Dec 2002 → Jul 2013	HIV infectious disease, pneumococcal infection	Henry M. Jackson Foundation for the Advancement of Military Medicine	Completed	No outcome recorded

Phase 415 trials
Phase 4	NCT05480436 Comparator	Aug 2022 → Jan 2023	COVID-19, hemolytic anemia	China National Biotec Group Company Limited	Unknown	No outcome recorded
Phase 4	NCT04989465 Comparator	Sep 2021	pneumococcal infection	Sinovac Biotech Co., Ltd	Completed	No outcome recorded
Phase 4	NCT04974294 Comparator	Jul 2021 → Jul 2023	streptococcal pneumonia	Liverpool School of Tropical Medicine	Unknown	No outcome recorded
Phase 4	NCT04953325 Comparator	Jul → Oct 2021	COVID-19	Sinovac Research and Development Co., Ltd.	Completed	No outcome recorded
Phase 4	NCT03104075 Comparator	Apr 2017 → Dec 2019	pneumonia	The Jackson Laboratory	Completed	No outcome recorded
Phase 4	NCT03762824 Comparator	Jun 2016 → Sep 2018	Sjogren syndrome, rheumatoid arthritis, spondyloarthropathy, systemic lupus erythematosus +1	Region Skane	Completed	No outcome recorded
Phase 4	NCT02447718 Comparator	Nov 2015 → Mar 2018	acute lymphoblastic leukemia	Canadian Immunization Research Network	Completed	No outcome recorded
Phase 4	NCT02062281 Comparator	Nov → Dec 2013	influenza, pneumococcal infection	Jiangsu Province Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 4	NCT03095326 Background	Sep 2013 → Feb 2014	pneumococcal infection, thalassemia	Faculty of Medicine, University of Indonesia	Completed	No outcome recorded
Phase 4	NCT01947010 Comparator	Jul 2013 → Aug 2014	Crohn disease	Statens Serum Institut	Completed	No outcome recorded
Phase 4	NCT01781871 Comparator	Jan 2013 → Oct 2017	—	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 4	NCT02582047 Comparator	Oct → Dec 2012	influenza, pneumococcal infection	Korea University Guro Hospital	Completed	No outcome recorded
Phase 4	NCT00836641 Comparator	Oct 2006 → Oct 2008	asthma	Johann Wolfgang Goethe University Hospital	Completed	No outcome recorded
Phase 4	NCT01402245 Comparator	Jan 2005 → Jun 2010	streptococcal pneumonia	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 4	NCT00023504 Comparator	Jun 2002 → May 2017	immunodeficiency disease	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded

Phase not applicable3 trials
—	NCT02726347 Comparator	Apr 2016 → Apr 2018	asthma	National Jewish Health	Unknown	No outcome recorded
—	NCT02547493 Comparator	Mar 2016 → Jan 2021	rheumatoid arthritis	University Hospital, Montpellier	Completed	No outcome recorded
—	NCT02538211 Comparator	Sep 2015 → Jan 2017	Rotavirus infection, post-bacterial disorder, streptococcal pneumonia, tetanus	Academic Medical Center - University of Amsterdam	Completed	No outcome recorded

Evidence & citations 37 cited values

Every value below carries the sentence it was read from. 184 sources stand behind the page.

Field	Value	Cited text
Known as	Pneumovax-23	“Multicentre Immune Memory Study in Healthy Children Following a 3 Dose Primary Vaccination With Prevenar or GSK Biologicals' Pneumococcal Conjugate Vaccine Via the...” NCT00333450 ↗ 46 “pneumococcal vaccination with either the 23-valent pneumococcal polysaccharide vaccine PPV-23 (Pneumovax-23) alone or the 13-valent pneumococcal conjugate vaccine PCV-13...” NCT03039491 ↗ “One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.” NCT04875819 ↗ “Pneumovax 23 (Pneumococcal Vaccine Polyvalent) will be administered at the single 0.5ml dose, by intramuscular injection with routine clinical care.” NCT03104075 ↗ “single dose of the control 23-valent pneumococcal polysaccharide vaccine (23PPV; Pneumovax23™, Sanofi Pasteur MSD) followed by placebo” PMID 24607003 ↗ Mar 2014 “single 0.5 ml sub-cutaneous dose of 23 valent pneumococcal polysaccharide vaccine (Pneumovax 23) to compare the dynamics” NCT03460730 ↗ “23PS group: Aventis Pasteurs' 23-valent polysaccharide pneumococcal vaccine (Pneumovax 23) + DTPa-HBV-IPV/Hib;” NCT00307567 ↗ “Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.” NCT02045836 ↗ “Participants first received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).” NCT02707692 ↗ “Pneumovax 23: 0.5ml IM at screening” NCT00785967 ↗ “GCflu and Pneumovax-23” NCT02582047 ↗ “PNEUMOVAX™ 23” NCT00535730 ↗ NCT03921424 ↗ NCT00169234 ↗ NCT00170612 ↗ NCT02285036 ↗ NCT02225587 ↗ NCT02260882 ↗ NCT02097589 ↗ NCT01513551 ↗ NCT05346302 ↗ NCT00307008 ↗ NCT02308540 ↗ NCT04583618 ↗ NCT02543918 ↗ NCT05667740 ↗ NCT05982314 ↗ NCT02072525 ↗ NCT02447718 ↗ NCT05170399 ↗ NCT02218697 ↗ NCT00307528 ↗ NCT02232191 ↗ NCT03480802 ↗ NCT02429531 ↗ NCT03480763 ↗ NCT00479323 ↗ NCT05163834 ↗ NCT04460235 ↗ NCT03547167 ↗ NCT00535730 ↗ NCT04481243 ↗ NCT02045836 ↗ NCT04168190 ↗ NCT01734239 ↗ NCT04665050 ↗ NCT03565900 ↗
Known as	23-Valent Pneumococcal Polysaccharide Vaccination	“PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)” NCT02260882 ↗
Known as	23-valent pneumococcal polysaccharide vaccine	“Influenza Vaccine recommended by World Health Organization(WHO) in that year and imported 23-Valent Pneumococcal Polysaccharide Vaccine approved by China Food and Drug...” NCT03449459 ↗ 37 “Adults ≥65 years of age were enrolled into 1 of 3 cohorts based on their prior pneumococcal vaccination history (23-valent pneumococcal polysaccharide vaccine [PPSV23], PCV13,...” PMID 34839993 ↗ Nov 2021 “The active control vaccine is a 23-valent pneumococcal polysaccharide vaccine (23-valent pneumococcal polysaccharide vaccine, PPSV23) produced by the Chengdu Institute of...” NCT06678620 ↗ “The active control vaccine is a 23-valent pneumococcal polysaccharide vaccine (23-valent pneumococcal polysaccharide vaccine, PPSV23) produced by the Chengdu Institute of...” NCT06678607 ↗ “an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine” PMID 35931636 ↗ Jul 2022 “assigned 340 pregnant Bangladeshi mothers to receive either trivalent inactivated influenza vaccine, or 23-valent pneumococcal polysaccharide vaccine during the third trimester.” PMID 23967126 ↗ Aug 2013 “To evaluate the safety and immunogenicity of a newly 23-valent pneumococcal polysaccharide vaccine (PPV23), a phase Ⅲ clinical trial was conducted in population aged ≥ 2 years.” PMID 30215583 ↗ Sep 2018 “23-valent Pneumococcal Polysaccharide Vaccine, produced by Chengdu Institute of Biological Products Co., Ltd. One dose, intramuscular.” NCT07640841 ↗ “This an open phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.” NCT04989465 ↗ “Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.” NCT01451086 ↗ “The 23-valent pneumococcal polysaccharide vaccine (PPV23) produced by Chengdu Institute of Biological Products” NCT07025876 ↗ “A 23-valent pneumococcal polysaccharide vaccine (PPV-23) has been licensed in the United States since 1983” NCT00153543 ↗ “a 23-valent pneumococcal polysaccharide vaccine (PPV23) in 1800 healthy Chinese adults aged 40-65 y” PMID 41165164 ↗ Oct 2025 “the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.” NCT05499351 ↗ “23-valent pneumococcal polysaccharide vaccine (PPV23)” PMID 29722823 ↗ Jun 2018 “23-valent pneumococcal polysaccharide vaccine (PPV23)” NCT04559204 ↗ “23-valent pneumococcal polysaccharide vaccine” NCT03313050 ↗ NCT00706550 ↗ NCT03802994 ↗ NCT01163747 ↗ NCT07600983 ↗ NCT00427895 ↗ NCT06314867 ↗ NCT05815264 ↗ NCT05471531 ↗ NCT02062281 ↗ NCT03762824 ↗ NCT04701788 ↗ NCT02558751 ↗ NCT06044077 ↗ NCT00282308 ↗ NCT02097849 ↗ NCT06703203 ↗ NCT00574548 ↗ NCT04700618 ↗ NCT04278248 ↗ NCT04953325 ↗ NCT01646398 ↗
Known as	23-valent Pneumococcal Polysaccharide Vaccine (PPV23)	“23-valent Pneumococcal Polysaccharide Vaccine (PPV23)” NCT06708286 ↗ 1 “23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）” NCT06056050 ↗
Known as	23-valent pneumococcal vaccine	“About 20% of patients with pneumococcal pneumonia in our previous study had been vaccinated with the only vaccine currently in use for adults, namely 23-valent pneumococcal...” NCT00304382 ↗
Known as	23-valent polysaccharide pneumococcal vaccine	“23PS group: Aventis Pasteurs' 23-valent polysaccharide pneumococcal vaccine (Pneumovax 23) + DTPa-HBV-IPV/Hib;” NCT00307567 ↗ 2 NCT01505855 ↗ NCT07418372 ↗
Known as	23-valent PPV	“* Intervention: investigational 23-valent PPV” NCT02451969 ↗
Known as	23PPV	“single dose of the control 23-valent pneumococcal polysaccharide vaccine (23PPV; Pneumovax23™, Sanofi Pasteur MSD) followed by placebo” PMID 24607003 ↗ Mar 2014
Known as	23vPPV	“Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.” NCT02062281 ↗
Known as	23vPS	“23-valent Pneumococcal Polysaccharide Vaccine (23vPS)” NCT00427895 ↗
Known as	PN23	“In a study of older adults, first and second doses of 23-valent pneumococcal polysaccharide vaccine (PN23) induced IgG increases for all 8 vaccine serotypes tested.” PMID 21860256 ↗ Sep 2011
Known as	Pneumo23	“Primed group: 50 subjects who previously received 4 doses of GSK Biologicals' 11Pn-PD vaccine will receive 1 dose of Pneumo 23 Unprimed group (Control): 50 subjects who...” NCT00169507 ↗ 20 “PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the...” NCT02547493 ↗ “All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.” NCT02538211 ↗ “There are two types of anti-pneumococcal vaccines: firstly a polysaccharide, Pneumo23® (PSV-23®) vaccine and secondly a conjugate, Prevenar13® vaccine.” NCT02255227 ↗ “receive either Pneumovax (or Pneumo23 according to standard use at site) or heptavalent pneumococcal conjugate vaccine (Prevnar)” NCT00137605 ↗ “23-valent pneumococcal capsular polysaccharide vaccine (Pneumo23(®) [PPV23], Sanofi Pasteur)” PMID 25424793 ↗ 2014 “The Pneumo23® has been for a long time the only vaccine recommended in adults” NCT02279589 ↗ “Pneumo23® or Pneumovax® polysaccharide vaccine (PPSV)” NCT02052154 ↗ NCT00368186 ↗ NCT00339157 ↗ NCT02255227 ↗ NCT00707798 ↗ NCT00999739 ↗ NCT02274415 ↗ NCT00594347 ↗ NCT00756067 ↗ NCT02279589 ↗ NCT00327665 ↗ NCT02787863 ↗ NCT01942174 ↗ NCT00611663 ↗
Known as	Pneumo23 (23valent polysaccharide pneumococcal vaccine)	“Pneumo23 (23valent polysaccharide pneumococcal vaccine)” NCT00999739 ↗
Known as	Pneumo23/Pneumovax	“Pneumo23/Pneumovax” NCT02547493 ↗
Known as	pneumococcal 23v polysaccharide vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00560950 ↗
Known as	Pneumococcal polysaccharide vaccine	“Pneumococcal polysaccharide vaccine(Pneumovax®) is suboptimal in this patient group.” NCT01781871 ↗ 7 NCT05028634 ↗ NCT00964769 ↗ NCT00788151 ↗ NCT00919321 ↗ NCT00622843 ↗ NCT01402245 ↗ NCT00257127 ↗
Known as	Pneumococcal polysaccharide vaccine 23 valent	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03039491 ↗
Known as	pneumococcal polyvalent vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00499577 ↗ 6 NCT01351896 ↗ NCT00046852 ↗ NCT00445484 ↗ NCT01239875 ↗ NCT05183854 ↗ NCT05417165 ↗
Known as	Pneumococcal Vaccine Polyvalent	“PNEUMOVAX(TM) 23 Vaccine (Pneumococcal Vaccine Polyvalent, Merck & Co., Inc.)” NCT00560950 ↗ 1 NCT05815264 ↗
Known as	Pneumococcal Vaccine, Polyvalent (23-valent)	“Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23” NCT00535730 ↗
Known as	Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02719379 ↗
Known as	Pneumovax	“PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the...” NCT02547493 ↗ 25 “Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company” NCT01942174 ↗ “single subcutaneous injection of 0.5 ml Pneumovax® (Sanofi Pasteur MSD AB, Lyon, France) (PPSV23)” NCT02806284 ↗ “a 13-valent conjugate vaccine (Prevenar®) and a 23-valent polysaccharide vaccine (Pneumovax®)” NCT04214444 ↗ “0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs” NCT01414504 ↗ “Pneumo23® or Pneumovax® polysaccharide vaccine (PPSV)” NCT02052154 ↗ “PPV pneumococcal vaccine (Pneumovax®)” NCT03095326 ↗ NCT00023504 ↗ NCT00152802 ↗ NCT00829595 ↗ NCT00143780 ↗ NCT01781871 ↗ NCT01892618 ↗ NCT07543198 ↗ NCT03873727 ↗ NCT01947010 ↗ NCT00589394 ↗ NCT00137605 ↗ NCT02126384 ↗ NCT00457977 ↗ NCT03460730 ↗ NCT01307449 ↗ NCT00304382 ↗ NCT00836641 ↗ NCT06474377 ↗ NCT02707692 ↗
Known as	PneumovaxR	“In a prospective study, serological responses and opsonic activity towards Streptococcus pneumoniae were measured in 60 HIV-infected patients and 25 controls after the...” PMID 8580899 ↗ Sep 1995
Known as	PNU-IMUNE23	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00133549 ↗
Known as	polyvalent pneumococcal vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00493324 ↗
Known as	PPS23	“Prevenar13 (PCV13) and Pneumovax (PPS23)” NCT03873727 ↗
Known as	PPSV23	“Day 1 Immunization Pre-NT-I7:Td and Polio Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1 Day 106: Hep B#2 (Optional) 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2,...” NCT04054752 ↗ 22 “The polyvalent (23-valent) pneumococcal vaccine, PPSV23, is the active comparator.” NCT05569954 ↗ “initial 13-valent PCV (PCV13) or 23-valent PPSV (PPSV23)” PMID 24606865 ↗ Mar 2014 NCT05393037 ↗ NCT04265911 ↗ NCT02012309 ↗ NCT06678607 ↗ NCT03835975 ↗ NCT05464420 ↗ NCT06678620 ↗ NCT03803202 ↗ NCT05633992 ↗ NCT03760146 ↗ NCT03313037 ↗ NCT05316831 ↗ NCT04875533 ↗ NCT05827874 ↗ NCT01381367 ↗ NCT05696080 ↗ NCT03260790 ↗ NCT02806284 ↗ NCT05420961 ↗ NCT06177912 ↗
Known as	PPSV23=Pneumovax,	“PPSV23=Pneumovax,” NCT02806284 ↗
Known as	PPV	“Pneumococcal polysaccharide vaccine (PPV)” NCT00919321 ↗
Known as	PPV23	“pneumococcal vaccination with either the 23-valent pneumococcal polysaccharide vaccine PPV-23 (Pneumovax-23) alone or the 13-valent pneumococcal conjugate vaccine PCV-13...” NCT03039491 ↗ 29 “To evaluate the safety and immunogenicity of a newly 23-valent pneumococcal polysaccharide vaccine (PPV23), a phase Ⅲ clinical trial was conducted in population aged ≥ 2 years.” PMID 30215583 ↗ Sep 2018 “a third booster dose of SARS-CoV-2 inactivated vaccine (CoronaVac), inactivated quadrivalent influenza vaccine (IIV4), and 23-valent pneumococcal polysaccharide vaccine (PPV23)” PMID 39229259 ↗ Aug 2024 “PPV23 produced by Chengdu Institute of Biological Products is a formulation with each vial containing 0.5 ml, and the dosage is 0.5 ml per person per administration.” NCT07035054 ↗ “They received an injection of 13-valent conjugate vaccine (PCV13), followed by an injection of 23-valent polysaccharide vaccine (PPV23) at least 2 months later.” NCT04460235 ↗ “A 23-valent pneumococcal polysaccharide vaccine (PPV-23) has been licensed in the United States since 1983” NCT00153543 ↗ “a 23-valent pneumococcal polysaccharide vaccine (PPV23) in 1800 healthy Chinese adults aged 40-65 y” PMID 41165164 ↗ Oct 2025 “the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.” NCT05499351 ↗ “23-valent pneumococcal capsular polysaccharide vaccine (Pneumo23(®) [PPV23], Sanofi Pasteur)” PMID 25424793 ↗ 2014 “PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)” NCT02260882 ↗ “23-valent pneumococcal polysaccharide vaccine (referred to as PPV23)” NCT07600983 ↗ “PNEUMOVAX® 23 (pneumococcal vaccine: PPV23)” PMID 20980796 ↗ Nov 2010 NCT00153543 ↗ NCT04559204 ↗ NCT07025876 ↗ NCT06056050 ↗ NCT04790851 ↗ NCT06708286 ↗ NCT02515240 ↗ NCT03069703 ↗ NCT02285036 ↗ NCT05079152 ↗ NCT05480436 ↗ NCT02726347 ↗ NCT02637583 ↗ NCT05622942 ↗ NCT02492438 ↗ NCT04974294 ↗ NCT02717494 ↗ NCT03041051 ↗
Known as	PPV23 vaccine	“1 dose ( 0.5ml) of PPV23 vaccine” NCT07600983 ↗
Known as	PSV-23	“There are two types of anti-pneumococcal vaccines: firstly a polysaccharide, Pneumo23® (PSV-23®) vaccine and secondly a conjugate, Prevenar13® vaccine.” NCT02255227 ↗
Known as	PSV-23 vaccine	“23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection” NCT01505855 ↗
Known as	Td ADSORBED	“Td ADSORBED: 0.5ml IM at screening” NCT00785967 ↗
Known as	V110	“PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)” NCT02260882 ↗ 2 NCT05158140 ↗ NCT00127153 ↗
Modality	Vaccine	“using Pneumococcal vaccine immunization” NCT00023504 ↗
Route	Intramuscular	“Patients receive PCV intramuscularly prior to transplantation” NCT00046852 ↗